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UREMIC TOXICITY
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The uremic syndrome: Therapeutic-evaluative discordance. normally acquired or resulting from physiologic pro-
Significant discordances are observed between the therapeutic cesses in the organism . . .” [1]. It is difficult to improve
needs of patients with end-stage renal disease and the current on Bouchard’s definition, and the confident certainty ofemphasis in renal science and technologies. These discordances
Chauffard in the understanding of the pathogenesis doesmanifest in the observation that renal replacement therapies
not match his more masterly exposition of the difficultiesfail to attenuate the impact of the patient status at the time of
initiation of renal replacement on mortality and morbidity; in inherent in the study of uremia.
the failure to apply a rigorous approach for fluid management, The difficulties have been compounded by a flagrant
despite its technical simplicity; in the inadequacy of dialysis in discordance between progress in the treatment of uremiathe correction of deficient excretion of some solutes (phosphate
and the understanding of its pathogenesis. The goal ofand potassium), and in the greater impact of hormonal replace-
this essay is to examine a set of observations that illus-ment on outcome than that observed by dialytic techniques. We
suggest that these discordances find their root in the limited spec- trate this discordance, and offer a perspective for explor-
trum of uremic solute removal that is currently available with atory undertakings targeted at elucidating the patho-
various dialytic techniques, and we suggest that a re-examina- physiologic basis of the uremic state. This endeavor is madetion of the therapeutic targets in dialytic therapy may be needed
more complex by another set of discordances: the bewil-in order to supercede the therapeutic plateau at which the
dering and persistent discordance between the therapeu-therapy is currently fixed.
tic needs of the patient population and the directions and
emphasis in renal science and technologies. The follow-
ing statements encapsulate these discordances:In 1898, in the fifth volume of “Traite de Me´dicine
et de The´rapeutique,” a compendium of authoritative
• The status of patients when renal replacement isreviews in internal medicine antedating and dwarfing
initiated remains one of the most important deter-Osler’s seminal work, Professor Chauffard of the medical
minants of mortality and morbidity on renal replace-faculty of Paris at Hopital Cochin wrote a review on the
ment therapy, irrespective of the modality utilizedpathology of diseases of the kidney [1]. The first section
(hemodialysis [HD], peritoneal dialysis [PD], orof his review addressed uremia, and he summarizes the
transplantation).status of knowledge at his time with these prescient
• Replacement of renal excretory function that iswords: “At present, uremia is a very complex pathologic
technically elementary (e.g., fluid removal) has beensubject, filled with facts and theories, but with a solid
more critical to improving mortality and morbidityscientific structure and clear broad outlines. . . . Of all
outcomes than have sophisticated enhancements inthe questions raised by the subject of uremia, none is
solute removal.more complex nor has led to more controversy than the
• The correction of deficient renal excretory functionsquestion of its pathogenesis. It has been evident since
by nondialytic means remains necessary for somethe early works on the subject that it is a state of intoxica-
solutes (phosphate, in particular), and this correc-tion, but the nature of this intoxication, its origin and its
tion appears to have a greater effect on mortalitymechanisms remain to be defined. Current research has
and morbidity than dialytic corrections.shed a powerful light on all these issues and delineated
• Replacement of nonexcretory renal functions (hor-a scientific and almost complete pathogenesis of uremia”
monal functions, erythopoietin, vitamin D, etc.) by[1]. Chauffard goes on to quote the definition of uremia
nondialytic interventions has had a greater impactproposed by Bouchard: “Uremia is complex poisoning
on patient morbidity than advances in dialytic inter-to which contribute, in various measures, all the poisons
ventions.
• Enhancement of small solute removal in interven-
Key words: uremic toxins, mortality in dialysis. tional studies has failed to influence outcome. Tar-
geted removal of single solute groups (such as beta 2003 by the International Society of Nephrology
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Table 1. Predictors of outcome on dialysis outcome not withstanding [6–8], fluid removal has been
identified as a critical determinant of outcome [9], partic-Predictor Reference
ularly in view of the dominant role of cardiovascular mor-Age [17, 19]
tality in this population. Further optimization of thisResidual renal function [17, 20, 21]
Plasma albumin [17, 19] therapeutic goal is independent of any additional refine-
Nutritional status (defined as protein intake ments in the understanding of the pathophysiology of ure-or assessed by surrogate markers) [17, 22–24]
mia. The persistent marginal control of volume status re-Presence of comorbidities (notably diabetes) [19]
Existence of underlying cardiovascular flects a failure in approach, not a limitation of technology.
disease (LVH, previous CHF, PVD, or
macrovascular disease of any type, etc.) [19]
Indicators of chronic inflammatory status NONDIALYTIC CORRECTION OF
(CRP, IL-6, etc.) [22, 23, 25–27]
EXCRETORY FUNCTIONS
Dialytic therapies play a secondary role in the correc-
tion of calcium-phosphate derangements and the resul-
tant cardiovascular and skeletal consequences [10–13].2-microglobulin) by dialytic means (diffusion, con-
These derangements and their corrections have preoccu-vection, or adsorption) has been disappointingly in-
pied the renal community and negatively impacted pa-effective in reversing pathology linked to levels of
tient outcomes in significant ways. The neurologic, hema-these solutes.
tologic, and skeletal trade-offs of aluminum use are being
mirrored by the cardiovascular trade-offs of calcium-Each of the above statements, while clearly challeng-
containing phosphate binders. The role of dialytic thera-ing, is supported by robust and convincing data sets and
pies in the amelioration and/or genesis of the cardiovas-has implications for the design of interventions to correct
cular calcification syndrome remains to be thoroughlythe uremic state.
addressed. Dialytic therapies play a facilitatory role, in
that administration of critical pharmacologic agents oc-
PATIENT STATUS AT START OF DIALYSIS curs during dialysis. Nevertheless, the dialytic removal of
The assertion that the status of patients at the start of phosphate remains unsatisfactory, and synergy between
renal replacement has the greatest impact on their ulti- pharmacologic therapies and dialysis conditions is yet to
be achieved to a satisfactory degree. While modificationsmate outcome has been repeatedly verified for all three
in dialysis calcium are available in both hemodialysisforms of renal replacement therapy. For both hemodialy-
and peritoneal dialysis, systematic guidelines on theirsis and peritoneal dialysis, several measures at baseline
proper use remain underdeveloped.have been identified as outcome defining (Table 1). The
finding that preemptive transplantation is superior to
“vintage” transplantation (or transplantation after a pe- NONDIALYTIC CORRECTION OF
riod of dialysis) is concordant with this general theme NONEXCRETORY FUNCTIONS
[2–4]. These observations imply that either our renal re-
The introduction of erythropoietin and vitamin D ap-placement interventions fail to significantly modify cer-
pears to have had a greater impact on patient morbidity
tain outcome-determining factors, or even modulate them, and possibly mortality than any advance in detoxification
or that we are applying our renal replacement therapies technology [14–16]. Many of the signs and symptoms pre-
at a time when their ability to modulate these factors is viously attributed to uremia either resolved or were
greatly handicapped by disease history [5]. Some of the greatly ameliorated by the replacement of renal hor-
outcome-defining factors are clearly not modifiable by monal functions. While the efficacy of hormonal replace-
current or future dialytic interventions. Other factors, ment is modulated by detoxification efficiency, after a
however, should be amenable to salutary modifications, threshold of detoxification is reached, there appears to
and their persistent impact may reflect our current thera- be no further enhancement of response to erythropoie-
peutic failures. tin. The exploration of retained toxins that have a sup-
pressive effect on hemopoiesis has not been marshaled
in a therapeutic intervention beyond an attempt at ex-ELEMENTARY RENAL REPLACEMENT
plaining the reason patients on peritoneal dialysis have
Correction of fluid balance can be achieved by the an enhanced response to erythropoietin.
most elementary technology in dialysis. The focus of
current technologic endeavors is to refine it, address its
ENHANCEMENT OF SMALL SOLUTEsafety, and render it automated by intelligent closed-
REMOVAL AND OUTCOMESloop systems. The main goal, however, of removing fluid,
has been achieved since the advent of dialysis. The argu- Several interventional studies have indicated that en-
hancement of small solute removal in isolation has ament about the correlation between blood pressure and
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limited effect on mortality beyond a certain level of dial- tissue fibrosis our unifying theory takes on a permissive
ysis delivery [17]. It is of little consolation to state that the role, namely, that a broader removal of solutes, ranging
results of the HEMO study (abstract; Eknoyan G et al, from 5 to 35 Kd, may permit the optimum response to
J Amer Soc Nephrol 13:421A, 2002) (no effect of either replacement of specific biologic pharmaceuticals such as
dose or flux on mortality or morbidity overall) confirm erythropoietin and vitamin D.
the Dialysis Outcome Quality Initiative (DOQI) guide- It is clear from the above discourse that we advocate
lines! These results, and others, likely delineate the lim- significant changes in approach to the care of patients
ited horizon that the renal community has for defining with advanced CKD and that we believe that the limited
its therapeutic objectives. and narrow spectrum of solute removal may be contribu-
In consideration of the above disturbing observations, tory to the observed discordances. We have argued else-
is it possible to offer a recommended approach that may where [18] that a compelling reason to advocate a re-
alleviate some of the discordances? It is clear that a major examination of the permeability characteristics of dialysis
modification of approach is required. We need not ad- membranes is the strong clinical necessity to improve
dress here the issue of enhanced care of patients with the therapy of the uremic syndrome. There is cumulative,
chronic kidney disease (CKD) along its continuum. The but, as yet, not definitive proof that larger molecules
question arises, however, whether dialysis-responsive as- (and/or toxins bound to large proteins) are contributing
pects of CKD exist prior to the current levels of dialysis to the constellation of abnormalities that remain after
initiation. Can we ascribe the lack of effect of dialysis on current dialysis therapy is used [18]. We believe that a ra-
some of the outcome-defining factors to a delay in inter- tional framework for the consideration of a broader spec-
vention, allowing for irreversible effects and prolonged trum of toxin removal can be developed based on current
disease history? Modifications in approach in the dialytic science. Such an approach serving a specific and well-
phase are evident, notably, modification of cardiovascu- defined therapeutic goal needs to be examined. Nonspe-
lar risk by greater vigilance in volume control, an approach cific and non–target-defined broadening of permeabilit-
that requires little further technologic innovations. ies should not be pursued with inequity. A broad range
What concerns us presently, however, is whether mod- of solute removal will be valuable in the dialysis arma-
ifications in dialytic therapy can be proposed that will mentarium only when carefully designed with a solid ther-
bypass the innovative inertia of renal industries not offer- apeutic rationale. Current dialytic therapies offer at best
ing what renal scientists do not request. It is dishearten- an imperfect survival. It is time for science to seriously
ing to note that the renal community has failed to define attempt to outdo random micro incremental evolution!
the detoxification targets necessary for renal industries
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by endogenous renal function or dialysis is an important
determinant of clinical outcome in end-stage renal failure. REFERENCES
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